Viret Jean-Frederic 4
4 · Coherus BioSciences, Inc. · Filed Nov 19, 2020
Insider Transaction Report
Form 4
Viret Jean-Frederic
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-11-17−1,500→ 110,241 totalExercise: $13.50Exp: 2024-11-05→ Common Stock (1,500 underlying) - Sale
Common Stock, $0.0001 par value
2020-11-17$17.49/sh−1,995$34,896→ 38,769 total - Exercise/Conversion
Common Stock, $0.0001 par value
2020-11-17$13.50/sh+1,500$20,250→ 40,269 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $17.27 to $17.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F3]Includes 31,250 restricted stock units.
- [F4]Includes 341 shares acquired on November 13, 2020, pursuant to Issuer's employee stock purchase plan.
- [F5]All of the shares underlying this option are vested and exercisable as of the date hereof.